ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 1730/S. 670- Speeding Therapy Access Today Act; H.R. 483/S. 350 - Newborn Screening Saves Lives Act; H.R. 6000 Cures 2.0 Act; H.R. 6584 Diverse and Equitable Participation in Clinical Trials Act; S. 2706/H.R. 5030 Diversifying Investigations Via Equitable Research Studies for Everyone Trials Act; H.R. 6963 - Accelerated Approval Integrity Act; H.R. 6996 - Accelerating Access for Patients Act - General issues related to rare disease and orphan drugs; Reauthorization of the FDA User Fee Act; FDA modernization policy issues; Reauthorization of newborn screening programs; Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients; General issues related to health equity in rare disease and clinical trials; General issues related to diagnostics for patients with rare diseases Cancer screening, diagnosis & treatment Prescription drug electronic labeling H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19 - Lower Costs, More Cures Act; H.R. 5260 - Reduced Costs and Continued Cures Act; H.R. 5376 - Build Back Better Act H.R. 3085/S. 1548 -ENACT Act of 2021 H.R. 5585 - Advanced Research Project Agency-Health Act H.R. 2883, Stop Stalling Access to Affordable Medications Issues related to COVID-19 vaccines and therapies; Items related to the Administrations Cancer Moonshot Prescription Drug User Fee Act (PDUFA) H.R. 4128/S. 2209, VALID Act S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022 Pharmaceutical Innovation, generally;
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSIE AHN | — |
| ELIZABETH BROOKS | — |
| HELEN DWIGHT | — |
| THADDEUS FLOOD | — |
| AARON W HUNTER | — |
| KATIE JONES | — |
| CAROLINE QUAT | — |
Medicare/Medicaid MMM
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19 - Lower Costs, More Cures Act; H.R. 5260 - Reduced Costs and Continued Cures Act; H.R. 5376 - Build Back Better Act - General issues related to patient access to rare disease therapies, Part B and Part D drugs; Issues related to home infusion for Part B patients; Center for Medicare and Medicaid Innovation (CMMI) policy issues; Value-based payment arrangements; Efforts to improve coding, coverage, and access for rare disease therapies; Issues related to low volume Diagnosis Related Groups (DRGs) and rare therapies; General issues related to diagnostic reimbursement S. 1873/H.R. 1946 - Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021 Issues related to preventative services and screenings for underrepresented communities
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSIE AHN | — |
| ELIZABETH BROOKS | — |
| HELEN DWIGHT | — |
| THADDEUS FLOOD | — |
| AARON W HUNTER | — |
| KATIE JONES | — |
| CAROLINE QUAT | — |
Pharmacy PHA
H.R. 7559 and issues related to an appropriations hold on funding for a 2014 FDA rule that would provide electronic flexibilities related to package inserts
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSIE AHN | — |
| ELIZABETH BROOKS | — |
| HELEN DWIGHT | — |
| THADDEUS FLOOD | — |
| AARON W HUNTER | — |
| KATIE JONES | — |
| CAROLINE QUAT | — |
Trade (domestic/foreign) TRD
Issues relating to Intellectual Property protections for Covid-19 treatments and vaccines. H.R. 2873, the Affordable Prescriptions for Patients Through Promoting Competition Act. H.R. 2884, the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act. H.R. 2883, Stop Stalling Access to Affordable Medications H.R. 2891 Preserve Access to Affordable Generics and Biosimilars Act H.R. 4521 America COMPETES Act of 2022 S. 1435, the Affordable Prescriptions for Patients Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSIE AHN | — |
| ELIZABETH BROOKS | — |
| HELEN DWIGHT | — |
| THADDEUS FLOOD | — |
| AARON W HUNTER | — |
| KATIE JONES | — |
| CAROLINE QUAT | — |
Taxation/Internal Revenue Code TAX
H.R. 2623 - Camerons Law; H.R. 5376 - Build Back Better Act; Issues related to the Orphan Drug Tax Credit; Issues related to the deduction of research and development expenditures Issues related to corporate and international tax reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSIE AHN | — |
| ELIZABETH BROOKS | — |
| HELEN DWIGHT | — |
| THADDEUS FLOOD | — |
| AARON W HUNTER | — |
| KATIE JONES | — |
| CAROLINE QUAT | — |
Budget/Appropriations BUD
Appropriations, FY 2023; H.R 8239, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023 H.R 8237,Legislative Branch Appropriations Act, 2023
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSIE AHN | — |
| ELIZABETH BROOKS | — |
| HELEN DWIGHT | — |
| THADDEUS FLOOD | — |
| AARON W HUNTER | — |
| KATIE JONES | — |
| CAROLINE QUAT | — |
Copyright/Patent/Trademark CPT
Issues related to intellectual property, data exclusivity, patent eligibility & patent law reform S. 4417, the PTAB Reform Act TRIPS IP Waiver
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSIE AHN | — |
| ELIZABETH BROOKS | — |
| HELEN DWIGHT | — |
| THADDEUS FLOOD | — |
| AARON W HUNTER | — |
| KATIE JONES | — |
| CAROLINE QUAT | — |
Environment/Superfund ENV
Sustainability & Zero Carbon; Items related to environmental sustainability and our Ambition Zero Carbon efforts
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSIE AHN | — |
| ELIZABETH BROOKS | — |
| HELEN DWIGHT | — |
| THADDEUS FLOOD | — |
| AARON W HUNTER | — |
| KATIE JONES | — |
| CAROLINE QUAT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.